Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Depreciation & Amortization (CF) (2016 - 2025)

Iovance Biotherapeutics (IOVA) has disclosed Depreciation & Amortization (CF) for 11 consecutive years, with $3.7 million as the latest value for Q4 2025.

  • On a quarterly basis, Depreciation & Amortization (CF) rose 13.71% to $3.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $12.9 million, a 13.9% increase, with the full-year FY2025 number at $12.9 million, up 14.28% from a year prior.
  • Depreciation & Amortization (CF) was $3.7 million for Q4 2025 at Iovance Biotherapeutics, up from $3.0 million in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $3.7 million in Q4 2025 to a low of $2.0 million in Q3 2024.
  • A 3-year average of $3.0 million and a median of $3.0 million in 2023 define the central range for Depreciation & Amortization (CF).
  • Peak YoY movement for Depreciation & Amortization (CF): plummeted 30.45% in 2024, then soared 48.04% in 2025.
  • Iovance Biotherapeutics' Depreciation & Amortization (CF) stood at $3.0 million in 2023, then increased by 10.34% to $3.3 million in 2024, then rose by 13.71% to $3.7 million in 2025.
  • Per Business Quant, the three most recent readings for IOVA's Depreciation & Amortization (CF) are $3.7 million (Q4 2025), $3.0 million (Q3 2025), and $3.4 million (Q2 2025).